EMA Authorised: Jascayd (nerandomilast) — Boehringer Ingelheim International GmbH

View source ↗

Summary

EMA authorised Jascayd (nerandomilast) for idiopathic pulmonary fibrosis, awarded to Boehringer Ingelheim International GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• JASCAYD (NERANDOMILAST)

Snippet

Status: Authorised. Therapeutic area: Idiopathic Pulmonary Fibrosis. MAH: Boehringer Ingelheim International GmbH. Decision date: 15/07/2026